Conexeu Sciences Q3 Loss Widens to $7.7M; Cash Runway Shrinks, Going Concern Warning Reiterated
CNXU sits 19% above its 52-week low of $4.19.
Summary
Conexeu Sciences' Q3 loss widened to $7.7M, cash dropped to $2.0M, and the company reiterated its going concern warning with a shorter cash runway. Internal control weaknesses remain unresolved.
Key Events · Earnings and Guidance · CNXU
-
Q3 Net Loss Widens to $7.7M
Net loss for the three months ended July 31, 2026 was $7,725,651, up from $1,298,570 in the prior-year quarter, driven by a $3.3M increase in consulting expense and $1.1M increase in business development.
-
Cash Runway Shrinks; Going Concern Reiterated
Cash and equivalents fell to $1,971,408 from $4,808,965 at October 31, 2025. Management states existing cash is not sufficient to fund operations for the next twelve months and will fund a substantially shorter period than the 9-11 months estimated as of April 30, 2026.
-
Material Weakness and Ineffective Controls
A material weakness in internal control over financial reporting related to prepaid expenses remains under remediation. Disclosure controls and procedures were concluded ineffective as of July 31, 2026.
-
Subsequent $1.75M Warrant Exercise
On September 4, 2026, four warrant holders exercised 762,608 warrants at $2.30 per share for gross proceeds of $1,753,998, which management says provides additional near-term liquidity but does not resolve going concern doubt.
Analysis · CNXU · Industrial Applications And Services
Conexeu Sciences reported a $7.7M net loss for Q3 FY2026, up from $1.3M a year ago, driven by heavy consulting and stock-based compensation costs following its Nasdaq direct listing. Cash and equivalents fell to $2.0M from $4.8M at fiscal year-end, and management now says existing cash will fund operations for a substantially shorter period than the 9-11 months estimated just three months ago. The company reiterates substantial doubt about its ability to continue as a going concern. A material weakness in internal controls related to prepaid expenses remains unremediated, and disclosure controls were deemed ineffective. A subsequent $1.75M warrant exercise provides only near-term relief.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.7% of the 1013 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CNXU was trading at $5.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $133.8M. The 52-week trading range was $4.19 to $18.79. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.